What impact does disease rarity have on rare and orphan drug pricing?
As more pharmaceutical companies develop and launch drugs to treat rare diseases, reimbursement decisions indicate that payers are looking at a range of...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Price and access decisions are critical for maximizing the lifecycle value of an asset or franchise. Life sciences companies seeking to develop successful pricing and access strategies must navigate the complex and evolving interactions between customers and products, and must ensure that their decisions balance strategic and financial goals while enabling appropriate access and reimbursement to medical providers, patients, and caregivers.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.comAs more pharmaceutical companies develop and launch drugs to treat rare diseases, reimbursement decisions indicate that payers are looking at a range of...
In this first article of a three-part PharmaPhorum series exploring pricing in Europe, we discuss the role disease rarity plays in reimbursement decisions...